|
KMID : 1100720220420040473
|
|
Annals of Laboratory Medicine
2022 Volume.42 No. 4 p.473 ~ p.477
|
|
|
Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
|
|
Kim Tae-Yeul
Kim Ji-Youn
Shim Hyang-Jin
Yun Sun-Ae
Jang Ja-Hyun
Huh Hee-Jae
Kim Jong-Won
Lee Nam-Yong
|
|
|
Abstract
|
|
|
|
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses may pose enormous challenges to our healthcare system. We evaluated the performance of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparison with the BioFire Respiratory Panels 2 and 2.1 (RP2 and RP2.1; bioMerieux, Marcy l’Etoile, France), using 147 nasopharyngeal swabs. The limit of detection (LOD) of the PowerChek assay was determined using SARS-CoV-2, influenza A, and B RNA standards. The LOD values of the PowerChek assay for SARS-CoV-2 and influenza A and B were 1.12, 1.24, and 0.61 copies/μL, respectively. The positive and negative percent agreements of the PowerChek assay compared with RP2 and RP2.1 were 97.5% (39/40) and 100% (107/107) for SARS-CoV-2; 100% (39/39) and 100% (108/108) for influenza A; and 100% (35/35) and 100% (112/112) for influenza B, respectively. The performance of the PowerChek assay was comparable to that of RP2 and RP2.1 for detecting SARS-CoV-2 and influenza A and B, suggesting its use in diagnosing SARS-CoV-2 and influenza infections.
|
|
|
KEYWORD
|
|
|
PowerChek SARS-CoV-2, Influenza A&B Multiplex Real-Time PCR Kit, SARS-CoV-2, Influenza, Real-time PCR, Performance, Agreement
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|
|